PL2544537T3 - Pozajelitowe preparaty antybiotyków makrolidowych - Google Patents
Pozajelitowe preparaty antybiotyków makrolidowychInfo
- Publication number
- PL2544537T3 PL2544537T3 PL11754115T PL11754115T PL2544537T3 PL 2544537 T3 PL2544537 T3 PL 2544537T3 PL 11754115 T PL11754115 T PL 11754115T PL 11754115 T PL11754115 T PL 11754115T PL 2544537 T3 PL2544537 T3 PL 2544537T3
- Authority
- PL
- Poland
- Prior art keywords
- parenteral formulations
- macrolide antibiotics
- macrolide
- antibiotics
- parenteral
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000003120 macrolide antibiotic agent Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31241710P | 2010-03-10 | 2010-03-10 | |
| PCT/US2011/027984 WO2011112864A1 (en) | 2010-03-10 | 2011-03-10 | Parenteral formulations of macrolide antibiotics |
| EP11754115.1A EP2544537B1 (en) | 2010-03-10 | 2011-03-10 | Parenteral formulations of macrolide antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2544537T3 true PL2544537T3 (pl) | 2017-10-31 |
Family
ID=44563855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11754115T PL2544537T3 (pl) | 2010-03-10 | 2011-03-10 | Pozajelitowe preparaty antybiotyków makrolidowych |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20130045937A1 (enExample) |
| EP (1) | EP2544537B1 (enExample) |
| JP (1) | JP5890785B2 (enExample) |
| CN (2) | CN109091489A (enExample) |
| AU (1) | AU2011224238B2 (enExample) |
| CA (1) | CA2792616A1 (enExample) |
| DK (1) | DK2544537T3 (enExample) |
| ES (1) | ES2637072T3 (enExample) |
| PL (1) | PL2544537T3 (enExample) |
| SI (1) | SI2544537T1 (enExample) |
| WO (1) | WO2011112864A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601695B2 (en) | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
| EP2214484A4 (en) | 2007-10-25 | 2013-01-02 | Cempra Pharmaceuticals Inc | PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS |
| CN102245195B (zh) | 2008-10-24 | 2016-01-13 | 森普拉制药公司 | 使用含三唑的大环内酯的生物防御 |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| JP5914335B2 (ja) * | 2009-09-10 | 2016-05-11 | センプラ ファーマシューティカルズ，インコーポレイテッド | マラリア、結核、及びｍａｃ病の治療方法 |
| EP3009442B1 (en) | 2010-03-22 | 2019-06-19 | Cempra Pharmaceuticals, Inc. | Crystalline forms of a macrolide, and uses therefor |
| CA2799937A1 (en) | 2010-05-20 | 2011-11-24 | Cempra Pharmaceuticals, Inc. | Processes for preparing macrolides and ketolides and intermediates therefor |
| WO2012034058A1 (en) | 2010-09-10 | 2012-03-15 | Cempra Pharmaceuticals, Inc. | Hydrogen bond forming fluoro ketolides for treating diseases |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CA2868262A1 (en) * | 2012-03-27 | 2013-10-03 | Cempra Pharmaceuticals, Inc. | Parenteral formulations for administering macrolide antibiotics |
| HK1217665A1 (zh) | 2013-03-14 | 2017-01-20 | 森普拉制药公司 | 用於治療呼吸道疾病的方法及其製劑 |
| HK1218864A1 (zh) | 2013-03-15 | 2017-03-17 | 森普拉制药公司 | 用於制备大环内酯抗菌剂的收敛方法 |
| KR102363621B1 (ko) | 2013-04-04 | 2022-02-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 매크롤라이드 그리고 그의 제조방법 및 용도 |
| RU2015154737A (ru) | 2013-05-22 | 2017-06-27 | Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. | Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| JP2017523975A (ja) * | 2014-08-05 | 2017-08-24 | センプラ ファーマシューティカルズ，インコーポレイテッド | 経口抗菌薬粉末懸濁製剤 |
| CA2963815A1 (en) | 2014-10-08 | 2016-04-14 | President And Fellows Of Harvard College | 14-membered ketolides and methods of their preparation and use |
| CN105561298A (zh) | 2014-10-17 | 2016-05-11 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| WO2016154591A1 (en) | 2015-03-25 | 2016-09-29 | President And Fellows Of Harvard College | Macrolides with modified desosamine sugars and uses thereof |
| CA3144443A1 (en) * | 2019-06-28 | 2020-12-30 | Moleculin Biotech, Inc. | Method of reconstituting liposomal annamycin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| US20040019012A1 (en) * | 2002-02-22 | 2004-01-29 | Singh Satish K. | Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride |
| US7601695B2 (en) * | 2003-03-10 | 2009-10-13 | Optimer Pharmaceuticals, Inc. | Antibacterial agents |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| CN101045063B (zh) * | 2006-03-28 | 2011-01-26 | 广州朗圣药业有限公司 | 注射用克拉霉素水溶性制剂 |
| CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
-
2011
- 2011-03-10 AU AU2011224238A patent/AU2011224238B2/en not_active Ceased
- 2011-03-10 EP EP11754115.1A patent/EP2544537B1/en not_active Not-in-force
- 2011-03-10 PL PL11754115T patent/PL2544537T3/pl unknown
- 2011-03-10 ES ES11754115.1T patent/ES2637072T3/es active Active
- 2011-03-10 US US13/583,556 patent/US20130045937A1/en not_active Abandoned
- 2011-03-10 CN CN201811127818.4A patent/CN109091489A/zh active Pending
- 2011-03-10 JP JP2012557258A patent/JP5890785B2/ja active Active
- 2011-03-10 CN CN2011800150681A patent/CN102811616A/zh active Pending
- 2011-03-10 WO PCT/US2011/027984 patent/WO2011112864A1/en not_active Ceased
- 2011-03-10 CA CA2792616A patent/CA2792616A1/en not_active Abandoned
- 2011-03-10 SI SI201131266T patent/SI2544537T1/sl unknown
- 2011-03-10 DK DK11754115.1T patent/DK2544537T3/en active
-
2018
- 2018-03-12 US US15/918,098 patent/US20190054059A1/en not_active Abandoned
-
2019
- 2019-12-02 US US16/700,384 patent/US20200276150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109091489A (zh) | 2018-12-28 |
| EP2544537A1 (en) | 2013-01-16 |
| US20130045937A1 (en) | 2013-02-21 |
| JP5890785B2 (ja) | 2016-03-22 |
| US20200276150A1 (en) | 2020-09-03 |
| JP2013522229A (ja) | 2013-06-13 |
| SI2544537T1 (sl) | 2017-12-29 |
| EP2544537A4 (en) | 2014-05-14 |
| DK2544537T3 (en) | 2017-08-28 |
| AU2011224238B2 (en) | 2015-11-26 |
| AU2011224238A1 (en) | 2012-10-04 |
| EP2544537B1 (en) | 2017-05-10 |
| ES2637072T3 (es) | 2017-10-10 |
| WO2011112864A1 (en) | 2011-09-15 |
| CN102811616A (zh) | 2012-12-05 |
| CA2792616A1 (en) | 2011-09-15 |
| US20190054059A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2544537T3 (pl) | Pozajelitowe preparaty antybiotyków makrolidowych | |
| IL254005A0 (en) | Parenteral formulations for the administration of macrolide antibiotics | |
| IL237581B (en) | Derivatives of 6-oxo-pyrazinopyrrolopyrimidines | |
| ZA201105852B (en) | Antibiotic peptides | |
| EP2651958A4 (en) | Glycoside blends | |
| EP2485742A4 (en) | ANTIBIOTIC FORMULATIONS WITH REDUCED SIDE EFFECTS ON STOMACH AND DARM | |
| GB2487868B (en) | Lyophilized cake formulations | |
| ZA201304150B (en) | Ketolide compounds | |
| GB2482385B (en) | Controllable flameholder | |
| GB2482603B (en) | Rheometer | |
| PL2640598T3 (pl) | Izolator sekcyjny | |
| EP2593087A4 (en) | PARENTERAL FORMULATIONS OF ELACYTARABINE DERIVATIVES | |
| EP2545687A4 (en) | Fast channel probing | |
| IL213871A0 (en) | Anti-inflammatory macrolide | |
| EP2657244A4 (en) | glycoside | |
| IL213924A0 (en) | High speed serializer | |
| IL225690A0 (en) | Anti-inflammatory macrolides | |
| ZA201202350B (en) | Antibiotic compounds | |
| PL2407155T3 (pl) | Formulacje inekalcytolu | |
| IL221333A0 (en) | Topical antibiotic formulations | |
| EP2645103A4 (en) | GLYCOPEPTIDE NETWORK | |
| AU4366P (en) | PFS100 Scaevola humilis | |
| AU332041S (en) | Four piece - double sided - radius extrusion | |
| TWM388848U (en) | Structure of lollipop | |
| GB201005923D0 (en) | Sample stabilisation |